# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001104659-26-057100
Filing Date
2026-05-07
Accepted
2026-05-07 16:05:22
Documents
81
Period of Report
2026-03-31

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | crvs-20260331x10q.htm iXBRL | 10-Q | 1764800
2 | EX-31.1 | crvs-20260331xex31d1.htm | EX-31.1 | 11826
3 | EX-31.2 | crvs-20260331xex31d2.htm | EX-31.2 | 11764
4 | EX-32.1 | crvs-20260331xex32d1.htm | EX-32.1 | 11817
5 | GRAPHIC | crvs-20260331x10q007.jpg | GRAPHIC | 52299
6 | GRAPHIC | crvs-20260331x10q008.jpg | GRAPHIC | 65247
7 | GRAPHIC | crvs-20260331x10q009.jpg | GRAPHIC | 53164
8 | GRAPHIC | crvs-20260331x10q010.jpg | GRAPHIC | 49895
9 | GRAPHIC | crvs-20260331x10q011.jpg | GRAPHIC | 48513
10 | GRAPHIC | crvs-20260331x10q012.jpg | GRAPHIC | 67674
| Complete submission text file | 0001104659-26-057100.txt |  | 8113150

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
11 | EX-101.SCH | crvs-20260331.xsd | EX-101.SCH | 42656
12 | EX-101.CAL | crvs-20260331_cal.xml | EX-101.CAL | 53897
13 | EX-101.DEF | crvs-20260331_def.xml | EX-101.DEF | 208112
14 | EX-101.LAB | crvs-20260331_lab.xml | EX-101.LAB | 402958
15 | EX-101.PRE | crvs-20260331_pre.xml | EX-101.PRE | 327842
85 | EXTRACTED XBRL INSTANCE DOCUMENT | crvs-20260331x10q_htm.xml | XML | 1190239

Mailing Address 901 GATEWAY BLVD, THIRD FLOOR SOUTH SAN FRANCISCO CA 94080
Business Address 901 GATEWAY BLVD, THIRD FLOOR SOUTH SAN FRANCISCO CA 94080 (650) 900-4520
Corvus Pharmaceuticals, Inc. (Filer) CIK: 0001626971 (see all company filings)

EIN.: 464670809 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37719 | Film No.: 26953097
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)